Related Experiment Videos

Effects of methylphenidate on preschool children with ADHD: cognitive and behavioral functions

L M Musten1, P Firestone, S Pisterman

  • 1School of Psychology, University of Ottawa, Ontario, Canada.

Insights

Methylphenidate effectively improves attention and impulsivity in preschoolers with ADHD. While it enhances cognitive function, it does not impact compliance with parental requests.

Area of Science:

  • Pediatric Psychiatry
  • Neurodevelopmental Disorders
  • Pharmacology

Background:

  • Attention-deficit hyperactivity disorder (ADHD) is a prevalent neurodevelopmental disorder.
  • Early intervention in preschool-aged children with ADHD is crucial for long-term outcomes.
  • The efficacy and safety of methylphenidate in very young children require further investigation.

Purpose of the Study:

  • To evaluate the effects of methylphenidate on cognitive and behavioral functioning in preschool children with ADHD.
  • To assess the implications of methylphenidate treatment for compliance in this age group.
  • To examine potential dose-related side effects of methylphenidate.

Main Methods:

  • A double-blind, placebo-controlled study involving 31 children aged 4-6 years diagnosed with ADHD.
  • Administration of placebo, 0.3 mg/kg, and 0.5 mg/kg of methylphenidate twice daily.
  • Assessment using cognitive tests, parent rating scales, and interactive tasks with mothers.

Main Results:

  • Methylphenidate improved attention and reduced impulsivity, as evidenced by cognitive tests and parent reports.
  • Children showed enhanced attentional abilities and productivity in interactive settings.
  • No significant changes in compliance with parental requests were observed.
  • Mild side effects were noted, particularly at the higher dosage.

Conclusions:

  • Methylphenidate is a viable treatment option for improving the functioning of preschool-aged children with ADHD.
  • The therapeutic effects are comparable to those observed in school-aged children.
  • Further research is needed to address compliance challenges in methylphenidate-treated preschoolers.
Abstract

Related Concept Videos